Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 57 29 6 17
Adverse Event Associated with Cardiac Arrhythmia 72
Premature Cardiac Complex 72
Extrasystoles 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
cardiac arrhythmia:
Clinical modifier sudden death
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 115000
ICD10 33 I49.8 I49.9
MedGen 42 C0003811
UMLS 72 C0340464 C1560249

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 9, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Transmission across Chemical Synapses. The drugs Promethazine and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and lung, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

More information from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 32.6 SCN5A RYR2 KCNQ1 KCNH2
2 long qt syndrome 9 32.5 SCN5A KCNJ2
3 long qt syndrome 13 32.2 SCN5A KCNQ1 KCNH2
4 familial short qt syndrome 31.8 KCNQ1 KCNJ2 KCNH2
5 sick sinus syndrome 31.7 SCN5A RANGRF CACNA1C
6 arrhythmogenic right ventricular dysplasia, familial, 1 31.6 RYR2 JUP
7 long qt syndrome 3 31.6 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 ANK2
8 arrhythmogenic right ventricular dysplasia, familial, 8 31.3 RYR2 PKP2 JUP
9 ventricular fibrillation, paroxysmal familial, 1 31.3 SCN5A RYR2 KCNQ1 KCNH2 KCNE2 KCNE1
10 long qt syndrome 12 31.3 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
11 syncope 31.1 SCN5A KCNQ1 KCNJ2 KCNH2
12 idiopathic ventricular fibrillation, non brugada type 31.0 SCN5A DPP6
13 brugada syndrome 1 31.0 SCN5A KCNH2 AKAP9
14 third-degree atrioventricular block 30.9 SCN5A KCNE2
15 atrioventricular block 30.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1
16 atrial fibrillation 30.7 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
17 andersen cardiodysrhythmic periodic paralysis 30.6 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
18 sudden infant death syndrome 30.5 SCN5A RYR2 KCNQ1 KCNH2
19 catecholaminergic polymorphic ventricular tachycardia 30.4 SCN5A RYR2 KCNJ2 KCNH2 ANK2
20 right bundle branch block 30.3 SCN5A CACNA1C
21 paroxysmal ventricular fibrillation 30.2 SCN5A DPP6
22 atrial standstill 1 30.2 SCN5A PKP2 JUP
23 left bundle branch hemiblock 30.1 SCN5A PKP2 JUP
24 long qt syndrome 6 30.1 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
25 long qt syndrome 2 29.9 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
26 timothy syndrome 29.8 KCNQ1 KCNH2 KCNE1 CACNA1C
27 long qt syndrome 5 29.4 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
28 cardiac arrest 29.3 SCN5A RYR2 KCNQ1 KCNH2 DPP6 ANK2
29 arrhythmogenic right ventricular cardiomyopathy 29.3 SCN5A RYR2 PKP2 KCNH2 JUP ANK2
30 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 29.3 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 ANK2
31 short qt syndrome 29.3 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1 CACNA1C
32 familial atrial fibrillation 29.1 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
33 heart disease 29.0 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
34 long qt syndrome 1 28.8 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
35 jervell and lange-nielsen syndrome 1 28.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 CACNA1C
36 brugada syndrome 28.1 SCN5A RANGRF PKP2 KCNQ1 KCNH2 KCNE2
37 long qt syndrome 27.8 SCN5A RYR2 PKP2 KCNQ1 KCNJ2 KCNH2
38 dilated cardiomyopathy 27.7 SCN5A RYR2 PKP2 KCNQ1 KCNH2 JUP
39 metabolic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.8
40 intellectual developmental disorder with cardiac arrhythmia 12.8
41 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.7
42 cardiac arrhythmia, ankyrin-b-related 12.7
43 ventricular extrasystoles with syncope, perodactyly, and robin sequence 12.4
44 intellectual disability-cardiac arrhythmia syndrome due to gnb5 deficiency 12.4
45 extrasystoles, multiform ventricular, with short stature, hyperpigmentation and microcephaly 12.2
46 extrasystoles short stature hyperpigmentation microcephaly 12.2
47 muscular dystrophy, limb-girdle, autosomal recessive 25 12.1
48 ogden syndrome 11.9
49 tango2-related metabolic encephalopathy and arrhythmias 11.8
50 guillain-barre syndrome 11.4

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation First-Degree Atrioventricular Block
Heart Disease Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 32 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 32 HP:0006696

Symptoms via clinical synopsis from OMIM:

57
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 CACNA1C CPT2 GNB5 JUP KCNH2 KCNJ2
2 muscle MP:0005369 9.28 CACNA1C GNB5 JUP KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 4 60-87-7 4927
2
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
8
leucovorin Approved Phase 4 58-05-9 143 6006
9
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
10
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
11
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Methadone Approved, Illicit Phase 4 76-99-3 4095
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Adenosine Approved, Investigational Phase 4 58-61-7 60961
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
19
Bisoprolol Approved Phase 4 66722-44-9 2405
20
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
21
Insulin glargine Approved Phase 4 160337-95-1
22
Metformin Approved Phase 4 657-24-9 4091 14219
23
Insulin Lispro Approved Phase 4 133107-64-9
24
Glucagon Approved Phase 4 16941-32-5
25
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Insulin Aspart Approved Phase 4 116094-23-6 16132418
28
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
29
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
30
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
31
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
32
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
33
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
34
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
35
nivolumab Approved Phase 4 946414-94-4
36
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
39
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
40
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
41 Tocotrienol Investigational Phase 4 6829-55-6
42 Antiemetics Phase 4
43 Dermatologic Agents Phase 4
44 Anti-Allergic Agents Phase 4
45 Histamine H1 Antagonists Phase 4
46 Histamine Antagonists Phase 4
47
Histamine Phosphate Phase 4 51-74-1 65513
48 Antipruritics Phase 4
49 Serotonin 5-HT2 Receptor Antagonists Phase 4
50 Quetiapine Fumarate Phase 4 111974-72-2

Interventional clinical trials:

(show top 50) (show all 299)
# Name Status NCT ID Phase Drugs
1 Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids Unknown status NCT01967433 Phase 4 Diphenhydramine;Placebo
2 Changes of Heart Rate Variability in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
3 Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
4 Study on the Role of a Combination of Nutraceuticals (Ritmonutra) With an Effect on Benign Supraventricular and Ventricular Arrhythmias in Subjects Free of a Specific Organic Heart Disease. Completed NCT01647984 Phase 4
5 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind "Split-mouth" Controlled Trial. Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
6 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
7 CRYptogenic STroke And underLying AF Trial Completed NCT00924638 Phase 4
8 Supportive Measures in Treatment of Aluminum Phosphide Poisoning as a Trial to Reduce Mortality at Assiut University Hospital Completed NCT03879356 Phase 4 N-acetyl cysteine
9 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
10 Pilot Randomized Clinical Trial Comparing the Efficacy of Two Different Hypothermia Temperatures for Treatment of Comatose Patients Recovered From an Out-of-hospital Cardiac Arrest Completed NCT01155622 Phase 4
11 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia: Data Collection of Clinical Scar-related VT Cases Completed NCT00851279 Phase 4
12 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
13 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
14 Weaning Process in Elderly Intubated Patients Submitted to Inspiratory Muscle Training Completed NCT00922493 Phase 4
15 The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation: Single Center, Prospective, Double-Blind and Randomized Study Completed NCT02359370 Phase 4 Lidocaine;Magnesium Sulphate
16 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
17 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
18 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
19 Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial Completed NCT00597077 Phase 4
20 FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR Completed NCT01524705 Phase 4 "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)];Insulin glargine, metformin, prandial insulin
21 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
22 A Comparison of Isolating the Pulmonary Veins With the Cryoballoon Catheter Versus Radiofrequency Segmental Isolation:a Randomized Controlled Prospective Non-inferiority Trial Completed NCT00774566 Phase 4
23 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
24 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After Endoscopic Variceal Ligation: A Randomised Controlled Clinical Trial Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
25 Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients Recruiting NCT02982850 Phase 4 Dabigatran;Acetylsalicylic acid;Warfarin
26 Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure: the SWISS-APERO Randomized Clinical Trial Recruiting NCT03399851 Phase 4
27 Interaction Between Intravenous Magnesium Sulphate and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block - A Randomized, Double Blinded, Electrophysiological Study Recruiting NCT03497923 Phase 4 Magnesium Sulfate
28 Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study) Recruiting NCT02426944 Phase 4 NOAC
29 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
30 A Multicenter, Randomized, Double-Blind, Controlled Study of EXPAREL for Postsurgical Pain Management in Subjects Undergoing Open Lumbar Spinal Fusion Surgery Terminated NCT03015961 Phase 4 Bupivacaine HCl;EXPAREL and bupivacaine HCl
31 Dabigatran-related Effect on Progression of Atrial Fibrosis in Patients With Atrial Fibrillation Terminated NCT01546883 Phase 4 Dabigatran etexilate (Pradaxa)
32 Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance Withdrawn NCT02120560 Phase 4
33 Cardiovascular Safety Evaluation in Patients With Coronary Artery Disease During Physical Effort After Use Lodenafil Carbonate Withdrawn NCT00817830 Phase 4 lodenafil carbonate
34 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
35 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
36 Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia Completed NCT02652338 Phase 3
37 Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study) Completed NCT00965874 Phase 3 Magnesium Sulfate high dose;Magnesium Sulfate low dose;Placebos
38 Cardiac Arrhythmia Suppression Trial (CAST) Completed NCT00000526 Phase 3 encainide;flecainide;moricizine
39 A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension Completed NCT00461903 Phase 3 Perindopril
40 Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation Completed NCT02132767 Phase 3 Amiodarone;Rate Control
41 Study on Omega-3 Fatty Acids and Ventricular Arrhythmia, a Parallel, Placebo-Controlled, Double Blind Intervention Study Completed NCT00110838 Phase 3
42 Beta-Blocker Evaluation in Survival Trial (BEST) Completed NCT00000560 Phase 3 adrenergic beta antagonists
43 Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE) Completed NCT00000558 Phase 3 angiotensin-converting enzyme inhibitors
44 CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation Completed NCT00007605 Phase 3 Amiodarone;Sotalol
45 Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed NCT00000464 Phase 3 amiodarone;imipramine;mexiletine;procainamide;propafenone;quinidine;sotalol
46 Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation Completed NCT02250703 Phase 3 Midazolam;Dexmedetomidine
47 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed NCT00000531 Phase 3 amiodarone amiodarone;sotalol
48 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed NCT00000556 Phase 3 amiodarone;sotalol;propafenone;flecainide;quinidine;moricizine;disopyramide;procainamide;adrenergic beta antagonists;verapamil;diltiazem;digoxin
49 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
50 Phase III Study of Maintenance Treatment for Opiate Dependence With Heroin (Diamorphine) Compared to Methadone Completed NCT00268814 Phase 3 Diacetylmorphine;Methadone

Search NIH Clinical Center for Cardiac Arrhythmia

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Dopamine
Glycopyrronium

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 29

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

41
Heart, Testes, Lung, Brain, Kidney, Liver, Thyroid

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 5291)
# Title Authors PMID Year
1
KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population. 71
12442276 2002
2
Familial paroxysmal ventricular tachycardia in two sisters. 8
4129426 1974
3
Fatal familial cardiac arrhythmias. Histologic observations on the cardiac conduction system. 8
5016833 1972
4
FAMILIAL POLYTOPIC AND POLYMORPHIC EXTRASYSTOLES. 8
14115011 1964
5
Complex patterns of subcellular cardiac alternans. 38
31220466 2019
6
When Is Syncope Arrhythmic? 38
31378326 2019
7
A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention. 38
31281110 2019
8
circRNA-miRNA cross-talk in the transition from paroxysmal to permanent atrial fibrillation. 38
31097202 2019
9
Complex effects of continuous vasopressor infusion on fluid responsiveness during liver resection: A randomised controlled trial. 38
31261168 2019
10
Remodeling of myocardial energy and metabolic homeostasis in a sheep model of persistent atrial fibrillation. 38
31307785 2019
11
Alcohol use disorders and the heart. 38
31309639 2019
12
Cardiac arrhythmia detection using deep learning: A review. 38
31416598 2019
13
[Constellations of findings and derived treatment interventions in telemedical monitoring of patients with heart failure, cardiac arrhythmia or increased risk for sudden cardiac death : Recommendations of the working group 33 telemonitoring of the German Cardiac Society]. 38
31410560 2019
14
Clinical and genetic analysis of long QT syndrome in two Malay children. 38
31424047 2019
15
Adverse cardiac outcomes after pulmonary function testing with recent myocardial infarction. 38
31299467 2019
16
A left atrial appendage closure combined procedure review: Past, present, and future perspectives. 38
31042321 2019
17
A genome-wide positioning systems network algorithm for in silico drug repurposing. 38
31375661 2019
18
LMNA-Related Muscular Dystrophy with Clinical Intrafamilial Variability. 38
31410651 2019
19
Indication-specific event rates among hospitalized patients undergoing continuous cardiac monitoring. 38
31407351 2019
20
Concomitant Fahr's syndrome and thoracic ossification of the posterior longitudinal ligament caused by idiopathic hypoparathyroidism - case report. 38
31391033 2019
21
[Atrial fibrillation in patients with sepsis and non-cardiac infections]. 38
31396698 2019
22
Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records. 38
30928998 2019
23
Beta-blockers in asthma: myth and reality. 38
31352857 2019
24
Increased risk of sudden death in untreated Primary Carnitine Deficiency. 38
31373028 2019
25
Glibenclamide and HMR1098 normalize Cantú syndrome-associated gain-of-function currents. 38
31119887 2019
26
Percutaneous left atrial appendage closure in a patient with haemophilia and atrial fibrillation: a case report. 38
31369664 2019
27
Antiarrhythmic and proarrhythmic effects of subcutaneous nerve stimulation in ambulatory dogs. 38
30818091 2019
28
Assessment of left ventricle magnetic resonance temperature stability in patients in the presence of arrhythmias. 38
31397942 2019
29
Development of a Porcine Model of Coronary Stenosis Using Fully Percutaneous Techniques Suitable For Performing Cardiac Computed Tomography, CT-Perfusion Imaging and Fractional Flow Reserve. 38
30054125 2019
30
Clinical features of facioscapulohumeral muscular dystrophy 1 in childhood. 38
30663041 2019
31
Lessons learned from testing cardiac channelopathy and cardiomyopathy genes in individuals who died suddenly: A two-year prospective study in a large medical examiner's office with an in-house molecular genetics laboratory and genetic counseling services. 38
31436011 2019
32
CE: Original Research: Are Milk and Molasses Enemas Safe for Hospitalized Adults? A Retrospective Electronic Health Record Review. 38
31408025 2019
33
Structural Basis for Diltiazem Block of a Voltage-gated Ca2+ Channel. 38
31391290 2019
34
Postoperative Myocardial Injury in Middle-Aged and Elderly Patients Following Curative Resection of Esophageal Cancer With Aggressive or Standard Body Temperature Management: A Randomized Controlled Trial. 38
30676350 2019
35
Cardiac arrhythmia from epinephrine overdose in epidural test dose. 38
31333374 2019
36
Cardiac arrhythmia and opioids: Be watchful. 38
30885377 2019
37
Determination of the QT Interval in Left Bundle Branch Block: Development of a Novel Formula. 38
31292084 2019
38
Protective effects of Gαq-RGS2 signalling inhibitor in aminophylline induced cardiac arrhythmia. 38
31330058 2019
39
Sensitivity of the Mount Fuji Sign After Evacuation of Chronic Subdural Hematoma in Nonagenarians. 38
31356520 2019
40
The impact of a 21-day ultra-endurance ride on the heart in young, adult and older adult recreational cyclists. 38
30904280 2019
41
Left ventricular non-compaction; an unusual presentation with supraventricular tachycardia in the emergency department. 38
31358381 2019
42
Arrhythmogenic calmodulin E105A mutation alters cardiac RyR2 regulation leading to cardiac dysfunction in zebrafish. 38
30937913 2019
43
Electrocardiogram signal generation using electrical model of cardiac cell: application in cardiac ischemia. 38
31353984 2019
44
Updating the evidence on drugs to treat overactive bladder: a systematic review. 38
31346670 2019
45
The stationary wavelet transform as an efficient reductor of powerline interference for atrial bipolar electrograms in cardiac electrophysiology. 38
31239416 2019
46
Clinical and laboratory findings and survival time associated with cardiac cachexia in dogs with congestive heart failure. 38
31317600 2019
47
Challenges and opportunities for integrating genetic testing into a diagnostic workflow: heritable long QT syndrome as a model. 38
31287796 2019
48
Sudden unexpected cardiac death and postmortem identification of a novel RYR2 gene mutation. 38
31289932 2019
49
Safety and Risk of Major Complications With Diagnostic Cardiac Catheterization. 38
31284736 2019
50
Atrial fibrillation and chronic kidney disease conundrum: an update. 38
31321745 2019

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 107)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PKP2 NM_004572.3(PKP2): c.235C> T (p.Arg79Ter) single nucleotide variant Pathogenic rs121434420 12:33031955-33031955 12:32879021-32879021
2 KCNQ1 NM_000218.2(KCNQ1): c.1343del (p.Pro448fs) deletion Pathogenic rs397508087 11:2610034-2610034 11:2588804-2588804
3 KCNQ1 NM_000218.2(KCNQ1): c.1842_1844del (p.His614del) deletion Pathogenic rs397508101 11:2869044-2869046 11:2847814-2847816
4 PKP2 NM_004572.3(PKP2): c.1211dup (p.Val406fs) duplication Pathogenic rs397516989 12:33003867-33003867 12:32850933-32850933
5 KCNH2 NM_000238.3(KCNH2): c.3079dup (p.Leu1027fs) duplication Pathogenic rs794728465 7:150644489-150644489 7:150947401-150947401
6 KCNH2 NM_000238.3(KCNH2): c.2966-2_2967dup duplication Pathogenic rs794728464 7:150644601-150644604 7:150947513-150947516
7 KCNH2 NM_000238.3(KCNH2): c.2783_2789del (p.Gly928fs) deletion Pathogenic rs794728457 7:150644870-150644876 7:150947782-150947788
8 KCNH2 NM_000238.3(KCNH2): c.2777del (p.Pro926fs) deletion Pathogenic rs794728456 7:150644882-150644882 7:150947794-150947794
9 KCNH2 NM_000238.3(KCNH2): c.2053del (p.Arg685fs) deletion Pathogenic rs794728500 7:150648101-150648101 7:150951013-150951013
10 KCNH2 NM_000238.3(KCNH2): c.1815del (p.Ser606fs) deletion Pathogenic rs794728499 7:150648666-150648666 7:150951578-150951578
11 KCNH2 NM_000238.3(KCNH2): c.1201_1204dup (p.His402fs) duplication Pathogenic rs794728434 7:150649866-150649869 7:150952778-150952781
12 KCNH2 NM_000238.3(KCNH2): c.1142del (p.Gly381fs) deletion Pathogenic rs794728497 7:150649928-150649928 7:150952840-150952840
13 KCNH2 NM_000238.3(KCNH2): c.853_859del (p.Ala285fs) deletion Pathogenic rs794728428 7:150655204-150655210 7:150958116-150958122
14 KCNH2 NM_000238.3(KCNH2): c.809_812delinsAAAAGC (p.Thr270fs) indel Pathogenic rs794728426 7:150655251-150655254 7:150958163-150958166
15 KCNH2 NM_000238.3(KCNH2): c.735_754dup (p.Arg252fs) duplication Pathogenic rs794728425 7:150655309-150655328 7:150958221-150958240
16 KCNH2 NM_000238.3(KCNH2): c.3136del (p.Gln1046fs) deletion Pathogenic rs794728472 7:150644432-150644432 7:150947344-150947344
17 KCNH2 NM_000238.3(KCNH2): c.3105_3112dup (p.Val1038fs) duplication Pathogenic rs794728470 7:150644456-150644463 7:150947368-150947375
18 KCNH2 NM_000238.3(KCNH2): c.3096_3099dup (p.Pro1034fs) duplication Pathogenic rs794728467 7:150644469-150644472 7:150947381-150947384
19 KCNH2 NM_000238.3(KCNH2): c.373_374insGTGG (p.Phe125fs) insertion Pathogenic rs794728489 7:150656758-150656759 7:150959670-150959671
20 KCNH2 NM_000238.3(KCNH2): c.244_252dup (p.Ile82_Gln84dup) duplication Pathogenic rs794728476 7:150671854-150671862 7:150974766-150974774
21 KCNH2 NM_000238.3(KCNH2): c.154del (p.Cys52fs) deletion Pathogenic rs794728508 7:150671952-150671952 7:150974864-150974864
22 KCNH2 NM_000238.3(KCNH2): c.106del (p.Val36fs) deletion Pathogenic rs794728507 7:150672000-150672000 7:150974912-150974912
23 KCNH2 NM_000238.3(KCNH2): c.100del (p.Ala34fs) deletion Pathogenic rs794728506 7:150672006-150672006 7:150974918-150974918
24 PKP2 NM_004572.3(PKP2): c.2013del (p.Lys672fs) deletion Pathogenic rs764817683 12:32974422-32974422 12:32821488-32821488
25 TANGO2 NM_001283106.2(TANGO2): c.460G> A (p.Gly154Arg) single nucleotide variant Pathogenic rs752298579 22:20049061-20049061 22:20061538-20061538
26 TANGO2 NM_001283106.2(TANGO2): c.605+1G> A single nucleotide variant Pathogenic rs372949028 22:20049207-20049207 22:20061684-20061684
27 KCNQ1 NM_000218.2(KCNQ1): c.165_187del (p.Gly57fs) deletion Pathogenic rs794728563 11:2466493-2466515 11:2445263-2445285
28 TANGO2 NM_152906.5(TANGO2): c.57-1743_*10769del deletion Pathogenic 22:20029135-20062954 22:20041612-20075431
29 TANGO2 NM_152906.5(TANGO2): c.146-3605_451+2245del deletion Pathogenic
30 SCN5A NM_000335.4(SCN5A): c.4716C> T (p.Gly1572=) single nucleotide variant Pathogenic/Likely pathogenic rs754221948 3:38595864-38595864 3:38554373-38554373
31 PKP2 NM_004572.3(PKP2): c.14del (p.Gly5fs) deletion Pathogenic/Likely pathogenic rs397516996 12:33049652-33049652 12:32896718-32896718
32 RYR2 NM_001035.3(RYR2): c.14314G> A (p.Gly4772Ser) single nucleotide variant Likely pathogenic rs193922622 1:237972216-237972216 1:237808916-237808916
33 RYR2 NM_001035.3(RYR2): c.4040T> G (p.Met1347Arg) single nucleotide variant Likely pathogenic rs193922625 1:237754172-237754172 1:237590872-237590872
34 KCNE2 NM_172201.1(KCNE2): c.161T> C (p.Met54Thr) single nucleotide variant risk factor rs74315447 21:35742938-35742938 21:34370639-34370639
35 KCNE2 NM_172201.1(KCNE2): c.170T> C (p.Ile57Thr) single nucleotide variant Conflicting interpretations of pathogenicity rs74315448 21:35742947-35742947 21:34370648-34370648
36 ANK2 NM_001148.6(ANK2): c.11231C> A (p.Thr3744Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs121912705 4:114288920-114288920 4:113367764-113367764
37 ANK2 NM_001148.6(ANK2): c.11716C> T (p.Arg3906Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs121912706 4:114294462-114294462 4:113373306-113373306
38 AKAP9 NM_005751.4(AKAP9): c.4837A> G (p.Met1613Val) single nucleotide variant Conflicting interpretations of pathogenicity rs193922723 7:91670132-91670132 7:92040818-92040818
39 ANK2 NM_001148.6(ANK2): c.8166G> A (p.Met2722Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922637 4:114277940-114277940 4:113356784-113356784
40 CACNA1C NM_000719.7(CACNA1C): c.6031G> A (p.Val2011Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922615 12:2797859-2797859 12:2688693-2688693
41 CACNA1C NM_000719.7(CACNA1C): c.6307G> T (p.Ala2103Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs193922616 12:2800255-2800255 12:2691089-2691089
42 JUP NM_002230.4(JUP): c.909+6C> T single nucleotide variant Conflicting interpretations of pathogenicity rs193922705 17:39923625-39923625 17:41767373-41767373
43 RYR2 NM_001035.3(RYR2): c.5586C> T (p.Asp1862=) single nucleotide variant Conflicting interpretations of pathogenicity rs193922628 1:237778014-237778014 1:237614714-237614714
44 SCN1B NM_199037.3(SCN1B): c.751G> A (p.Val251Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs193922728 19:35524946-35524946 19:35034042-35034042
45 SCN5A NM_000335.4(SCN5A): c.4434+13C> T single nucleotide variant Conflicting interpretations of pathogenicity rs148598985 3:38597919-38597919 3:38556428-38556428
46 SNTA1 NM_003098.2(SNTA1): c.311-6G> C single nucleotide variant Conflicting interpretations of pathogenicity rs139532210 20:32026838-32026838 20:33439032-33439032
47 RYR2 NM_001035.3(RYR2): c.3251G> A (p.Arg1084Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs193922624 1:237729903-237729903 1:237566603-237566603
48 KCNH2 NM_000238.3(KCNH2): c.3140G> T (p.Arg1047Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs36210421 7:150644428-150644428 7:150947340-150947340
49 RYR2 NM_001035.3(RYR2): c.10230+20T> C single nucleotide variant Conflicting interpretations of pathogenicity rs74323916 1:237872887-237872887 1:237709587-237709587
50 CACNB2 NM_201590.2(CACNB2): c.1044+4_1044+7dupAGTA duplication Conflicting interpretations of pathogenicity rs1456201116 10:18823160-18823163 10:18534231-18534234

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 RYR2 KCNQ1 KCNJ2 GNB5 CACNA1C
2
Show member pathways
12.71 KCNQ1 KCNJ2 KCNH2 GNB5 AKAP9
3
Show member pathways
12.58 SCN5A RYR2 RANGRF KCNQ1 KCNJ2 KCNH2
4
Show member pathways
12.57 SCN5A RYR2 KCNQ1 KCNE1 CACNA1C
5 12.21 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1 GNB5
6
Show member pathways
11.92 RYR2 PKP2 JUP CACNA1C
7 11.88 SCN5A RYR2 KCNQ1 KCNH2
8
Show member pathways
11.84 KCNQ1 KCNJ2 KCNH2
9
Show member pathways
11.37 SCN5A RANGRF KCNQ1 KCNE2 KCNE1 CACNA1C
10 11.07 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2
11 10.78 KCNQ1 KCNJ2 KCNE1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosome GO:0005764 9.73 KCNQ1 KCNE2 KCNE1 ANK2
2 Z disc GO:0030018 9.63 SCN5A RYR2 KCNE1 JUP CACNA1C ANK2
3 sarcolemma GO:0042383 9.62 SCN5A RYR2 CACNA1C ANK2
4 T-tubule GO:0030315 9.54 SCN5A KCNJ2 ANK2
5 smooth endoplasmic reticulum GO:0005790 9.48 RYR2 KCNJ2
6 desmosome GO:0030057 9.46 PKP2 JUP
7 intercalated disc GO:0014704 9.43 SCN5A RANGRF PKP2 KCNJ2 JUP ANK2
8 voltage-gated potassium channel complex GO:0008076 9.17 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1 DPP6
9 membrane GO:0016020 10.25 SCN5A RYR2 RANGRF KCNQ1 KCNJ2 KCNH2
10 plasma membrane GO:0005886 10.1 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNJ2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 potassium ion transport GO:0006813 9.99 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
2 potassium ion transmembrane transport GO:0071805 9.97 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
3 regulation of ion transmembrane transport GO:0034765 9.95 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
4 protein localization to plasma membrane GO:0072659 9.93 PKP2 JUP DPP6 ANK2
5 cardiac muscle contraction GO:0060048 9.88 SCN5A RYR2 KCNQ1 KCNH2
6 ion transmembrane transport GO:0034220 9.87 SCN5A RYR2 CACNA1C
7 regulation of heart rate GO:0002027 9.86 SCN5A RYR2 RANGRF ANK2
8 cellular response to drug GO:0035690 9.85 KCNQ1 KCNH2 KCNE2
9 regulation of potassium ion transmembrane transport GO:1901379 9.84 KCNH2 KCNE2 KCNE1 DPP6
10 cellular response to cAMP GO:0071320 9.83 KCNQ1 KCNE1 AKAP9
11 potassium ion export across plasma membrane GO:0097623 9.83 KCNQ1 KCNH2 KCNE2 KCNE1
12 positive regulation of potassium ion transmembrane transport GO:1901381 9.81 KCNQ1 KCNJ2 KCNH2 KCNE1
13 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNQ1 KCNH2 KCNE2 KCNE1
14 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.79 RYR2 CACNA1C ANK2
15 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.79 RYR2 PKP2 CACNA1C
16 regulation of cardiac muscle cell contraction GO:0086004 9.78 SCN5A KCNJ2 ANK2
17 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.78 RYR2 PKP2 JUP CACNA1C
18 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 SCN5A KCNJ2 CACNA1C
19 regulation of membrane repolarization GO:0060306 9.77 KCNQ1 KCNJ2 KCNH2 KCNE2 AKAP9
20 atrial cardiac muscle cell action potential GO:0086014 9.76 SCN5A KCNQ1 ANK2
21 membrane repolarization GO:0086009 9.76 KCNQ1 KCNH2 KCNE2 KCNE1
22 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.73 KCNQ1 KCNJ2 KCNH2 KCNE1
23 cardiac muscle cell action potential involved in contraction GO:0086002 9.73 SCN5A PKP2 KCNJ2 KCNE2 KCNE1 CACNA1C
24 membrane repolarization during action potential GO:0086011 9.72 KCNQ1 KCNJ2 KCNH2 KCNE2 KCNE1
25 positive regulation of heart rate GO:0010460 9.71 RYR2 KCNQ1
26 regulation of cardiac muscle contraction GO:0055117 9.71 RYR2 ANK2
27 positive regulation of sodium ion transport GO:0010765 9.71 SCN5A PKP2
28 membrane depolarization during action potential GO:0086010 9.7 SCN5A KCNH2
29 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.7 KCNE2 KCNE1
30 calcium ion transport into cytosol GO:0060402 9.7 RYR2 CACNA1C
31 cellular response to epinephrine stimulus GO:0071872 9.7 RYR2 KCNQ1
32 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.7 SCN5A KCNQ1 KCNH2 KCNE2 KCNE1 ANK2
33 regulation of sodium ion transmembrane transport GO:1902305 9.69 SCN5A RANGRF
34 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.68 RYR2 ANK2
35 regulation of cardiac muscle cell action potential involved in regulation of contraction GO:0098909 9.68 RANGRF AKAP9
36 regulation of delayed rectifier potassium channel activity GO:1902259 9.68 KCNE2 KCNE1
37 SA node cell action potential GO:0086015 9.67 SCN5A ANK2
38 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.67 SCN5A KCNQ1
39 positive regulation of potassium ion transmembrane transporter activity GO:1901018 9.67 ANK2 AKAP9
40 bundle of His cell-Purkinje myocyte adhesion involved in cell communication GO:0086073 9.66 PKP2 JUP
41 sarcoplasmic reticulum calcium ion transport GO:0070296 9.65 RYR2 ANK2
42 membrane depolarization during SA node cell action potential GO:0086046 9.65 SCN5A ANK2
43 membrane depolarization during AV node cell action potential GO:0086045 9.65 SCN5A CACNA1C
44 desmosome assembly GO:0002159 9.64 PKP2 JUP
45 regulation of atrial cardiac muscle cell action potential GO:0098910 9.64 RYR2 ANK2
46 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.63 SCN5A CACNA1C
47 regulation of SA node cell action potential GO:0098907 9.62 RYR2 ANK2
48 ventricular cardiac muscle cell action potential GO:0086005 9.56 SCN5A RYR2 PKP2 KCNQ1 KCNH2 KCNE2
49 regulation of heart rate by cardiac conduction GO:0086091 9.36 SCN5A PKP2 KCNQ1 KCNJ2 KCNH2 KCNE2
50 ion transport GO:0006811 10.15 SCN5A RYR2 KCNQ1 KCNJ2 KCNH2 KCNE2

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.83 SCN5A RYR2 KCNQ1 CACNA1C
2 ion channel activity GO:0005216 9.8 SCN5A RYR2 KCNH2 CACNA1C
3 potassium channel activity GO:0005267 9.73 KCNQ1 KCNH2 KCNE2 KCNE1
4 voltage-gated ion channel activity GO:0005244 9.73 SCN5A KCNQ1 KCNJ2 KCNH2 KCNE2 CACNA1C
5 scaffold protein binding GO:0097110 9.71 SCN5A KCNQ1 KCNH2
6 voltage-gated potassium channel activity GO:0005249 9.71 KCNQ1 KCNH2 KCNE2 KCNE1
7 potassium channel regulator activity GO:0015459 9.67 KCNE2 KCNE1 DPP6 AKAP9
8 inward rectifier potassium channel activity GO:0005242 9.65 KCNJ2 KCNH2 KCNE2
9 protein kinase A regulatory subunit binding GO:0034237 9.63 RYR2 KCNQ1 AKAP9
10 delayed rectifier potassium channel activity GO:0005251 9.62 KCNQ1 KCNH2 KCNE2 KCNE1
11 protein kinase A catalytic subunit binding GO:0034236 9.56 RYR2 KCNQ1
12 alpha-catenin binding GO:0045294 9.55 PKP2 JUP
13 cell adhesive protein binding involved in bundle of His cell-Purkinje myocyte communication GO:0086083 9.51 PKP2 JUP
14 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.46 KCNQ1 KCNH2 KCNE2 KCNE1
15 ion channel binding GO:0044325 9.28 SCN5A RYR2 RANGRF PKP2 KCNQ1 KCNE2
16 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.26 KCNQ1 KCNJ2 KCNH2 KCNE1

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....